[go: up one dir, main page]

HRP940563B1 - Androstenone derivatives - Google Patents

Androstenone derivatives

Info

Publication number
HRP940563B1
HRP940563B1 HR940563A HRP940563A HRP940563B1 HR P940563 B1 HRP940563 B1 HR P940563B1 HR 940563 A HR940563 A HR 940563A HR P940563 A HRP940563 A HR P940563A HR P940563 B1 HRP940563 B1 HR P940563B1
Authority
HR
Croatia
Prior art keywords
androstenone
derivatives
androstenone derivatives
Prior art date
Application number
HR940563A
Other languages
English (en)
Inventor
Kenneth William Batchelor
Stephen Vernon Frye
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22407744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP940563(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of HRP940563A2 publication Critical patent/HRP940563A2/xx
Publication of HRP940563B1 publication Critical patent/HRP940563B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/14—Benz[f]indenes; Hydrogenated benz[f]indenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR940563A 1993-09-17 1994-09-16 Androstenone derivatives HRP940563B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12328093A 1993-09-17 1993-09-17

Publications (2)

Publication Number Publication Date
HRP940563A2 HRP940563A2 (en) 1997-02-28
HRP940563B1 true HRP940563B1 (en) 2000-10-31

Family

ID=22407744

Family Applications (1)

Application Number Title Priority Date Filing Date
HR940563A HRP940563B1 (en) 1993-09-17 1994-09-16 Androstenone derivatives

Country Status (41)

Country Link
US (2) US5565467A (fr)
EP (1) EP0719278B1 (fr)
JP (1) JP2904310B2 (fr)
KR (1) KR100364953B1 (fr)
CN (1) CN1057771C (fr)
AP (1) AP494A (fr)
AT (1) ATE162199T1 (fr)
AU (1) AU690925B2 (fr)
BG (1) BG62363B1 (fr)
BR (1) BR1100329A (fr)
CA (2) CA2462061A1 (fr)
CY (2) CY2219B1 (fr)
CZ (1) CZ286069B6 (fr)
DE (2) DE10399022I2 (fr)
DK (1) DK0719278T3 (fr)
EE (1) EE03241B1 (fr)
ES (1) ES2113127T3 (fr)
FI (1) FI115216B (fr)
GR (1) GR3026144T3 (fr)
HK (1) HK1004334A1 (fr)
HR (1) HRP940563B1 (fr)
HU (1) HU220060B (fr)
IL (1) IL110978A (fr)
IS (1) IS1713B (fr)
LU (1) LU91027I2 (fr)
MY (1) MY119778A (fr)
NL (1) NL300122I2 (fr)
NO (2) NO306117B1 (fr)
NZ (1) NZ274642A (fr)
OA (1) OA10575A (fr)
PE (1) PE15095A1 (fr)
PL (1) PL180002B1 (fr)
RO (1) RO117455B1 (fr)
RU (1) RU2140926C1 (fr)
SA (1) SA94150231B1 (fr)
SG (1) SG52650A1 (fr)
SI (1) SI0719278T1 (fr)
SK (1) SK281869B6 (fr)
TW (1) TW369521B (fr)
WO (1) WO1995007927A1 (fr)
ZA (2) ZA947118B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508033A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド ５α−レダクターゼ阻害剤としての３−オキソ−４−アザステロイドの新規１７−エステル，アミド及びケトン誘導体
AU5323694A (en) * 1992-10-06 1994-04-26 Merck & Co., Inc. 17beta -carboxanilides of 4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US5547957A (en) 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
FI961697A7 (fi) * 1993-10-21 1996-04-18 Merck & Co Inc 16-substituoidut-4-atsa-androstaani 5alfa-reduktaasi-isotsyymi-1-inhib iittorit
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US6001844A (en) * 1995-09-15 1999-12-14 Merck & Co., Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
US5872126A (en) * 1996-09-06 1999-02-16 Merck & Co., Inc. Methods and compositions for treating preterm labor
US5935968A (en) * 1997-03-17 1999-08-10 Merck & Co., Inc. Methods for treating polycystic ovary syndrome
GB9717428D0 (en) * 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
EP1032400A4 (fr) * 1997-10-28 2006-04-12 Merck & Co Inc Prevention de retention urinaire aigue precipitee
WO1999046279A2 (fr) * 1998-03-11 1999-09-16 Endorecherche, Inc. INHIBITEURS DE LA 17β-HYDROXYSTEROIDE DESHYDROGENASE DU TYPE 5 ET DU TYPE 3 ET METHODES D'UTILISATION ASSOCIEES
EP1321146A3 (fr) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibiteurs de la 17beta-hydroxysteroide deshydrogénase du type 5 et du type 3 ainsi que leurs méthodes d'utilisation
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
WO1999066915A2 (fr) * 1998-06-23 1999-12-29 Southern Illinois University At Carbondale Applications therapeutiques d'acides carboxyliques oestrogenes
KR20010101931A (ko) * 1999-02-03 2001-11-15 피터 지. 스트링거 α1-아드레날린성 수용체 길항제
PT1175433E (pt) 1999-05-04 2005-11-30 Strakan Int Ltd Glicosidos androgenos e sua actividade androgenica
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
CA2462456C (fr) * 2001-10-03 2010-05-04 Merck & Co., Inc. Androstane 17-beta-carboxamides en tant que modulateurs de recepteurs d'androgenes
JP4474921B2 (ja) * 2002-01-25 2010-06-09 旭硝子株式会社 ２，５−ビス（トリフルオロメチル）ニトロベンゼンの製造方法
JP2005524693A (ja) * 2002-04-24 2005-08-18 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 良性前立腺増殖症の治療又は急性尿閉の長期予防用の医薬組成物
CA2484173A1 (fr) * 2002-04-30 2003-11-13 Merck & Co., Inc. Derives de 4-azasteroide utilises comme modulateurs du recepteur de l'androgene
US7326717B2 (en) * 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
US7022854B2 (en) * 2003-07-17 2006-04-04 Dr. Reddy's Laboratories, Limited Forms of dutasteride and methods for preparation thereof
US20050059692A1 (en) * 2003-09-09 2005-03-17 Dr. Reddy's Laboratories Limited Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one
WO2005092341A1 (fr) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Therapie combinee destinee a reduire les symptomes des voies urinaires
US20080125403A1 (en) * 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
CA2576988A1 (fr) * 2004-08-25 2006-03-09 Merck & Co., Inc. Modulateurs du recepteur de l'androgene
US7998970B2 (en) * 2004-12-03 2011-08-16 Proteosys Ag Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders
US20060193804A1 (en) * 2005-02-24 2006-08-31 L'oreal Haircare use of cyclic amine derivatives
CA2602386A1 (fr) 2005-03-25 2006-10-05 Merck & Co., Inc. Traitement d'humains de sexe masculin par supplementation en testosterone associee a un inhibiteur de 5alpha-reductase
EP1945615A2 (fr) * 2005-11-10 2008-07-23 Dr. Reddy's Laboratories Ltd. Préparation de dutastéride
EP1897533A1 (fr) * 2006-09-08 2008-03-12 Revotar Biopharmaceuticals AG Utilisation de 1,6-Bis[3-(3-carboxyméthylphényl)-4-(2-alpha-D-mannopyranosyl-oxy)-phényl]hexane pour la préparation des compositions cosmétiques.
EP1946756A1 (fr) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Utilisation d'entacapone dans les compositions cosmétiques, dermatologiques et pharmaceutiques
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
US20090076057A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched dutasteride
EP2050436A1 (fr) 2007-12-21 2009-04-22 Siegfried Generics International AG Composition pharmaceutique qui comporte de la dutastéride
AR070313A1 (es) * 2008-01-03 2010-03-31 Gador Sa Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma
FR2929118B1 (fr) 2008-03-28 2010-05-07 Oreal Utilisation de l'association de madecassoside et/ou de terminoloside et d'une arginine pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
FR2929117B1 (fr) 2008-03-28 2010-05-07 Oreal Utilisation de l'association du 2,4-diaminopyrimidine 3-n-oxyde et du madecassosside et/ou du terminoloside pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
WO2009124300A2 (fr) 2008-04-03 2009-10-08 Hollis-Eden Pharmaceuticals, Inc. Formes à l’état solide d’un produit pharmaceutique
US20100048598A1 (en) * 2008-08-21 2010-02-25 Sateesh Kandavilli Topical compositions comprising 5-alpha reductase inhibitors
CN101759762B (zh) * 2008-11-06 2013-03-20 天津金耀集团有限公司 4ad在制备度他雄胺中的应用
US8563728B2 (en) * 2009-07-09 2013-10-22 Aurobindo Pharma Ltd. Process for the preparation of Dutasteride
FR2949052B1 (fr) 2009-08-13 2015-03-27 Oreal Procede de traitement cosmetique du cuir chevelu.
EP2468262A1 (fr) 2010-12-06 2012-06-27 Krka Tovarna Zdravil, D.D., Novo Mesto Composition pharmaceutique contenant de la dutastéride
WO2012162776A1 (fr) * 2011-06-03 2012-12-06 Eurofarma Laboratórios S.A Composition pharmaceutique pour le traitement de l'hyperplasie bénigne de la prostate
HU230730B1 (hu) 2011-06-30 2017-12-28 Richter Gedeon Nyrt Eljárás (5alfa,17béta)-N-[2,5-bisz-(trifluormetil)-fenil]-3-oxo-4-aza-5-androszt-1-én-17-karbonsavamid előállítására
CN103059098B (zh) * 2011-10-24 2015-04-01 成都国为医药科技有限公司 一种度他雄胺的制备方法
US9622981B2 (en) 2011-11-17 2017-04-18 Mylan Inc. Liquid-filled hard gel capsule pharmaceutical formulations
CN102382165B (zh) * 2011-12-02 2014-05-07 华润赛科药业有限责任公司 一种度他雄胺的制备方法
CN103554210A (zh) * 2012-01-05 2014-02-05 中国药科大学 甾体类5α-还原酶抑制剂、其制备方法及其医药用途
CN102532236B (zh) * 2012-01-05 2014-04-16 中国药科大学 甾体类5α-还原酶抑制剂、其制备方法及其医药用途
KR101976137B1 (ko) 2012-01-25 2019-05-09 한미약품 주식회사 두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법
PT2838533T (pt) 2012-04-16 2017-11-22 Univ Texas Composições e métodos de modulação da atividade de 15-pgdh
WO2014002015A1 (fr) 2012-06-25 2014-01-03 Ranbaxy Laboratories Limited Composition pharmaceutique comprenant du dutastéride
AU2014241816B9 (en) * 2013-03-14 2019-02-14 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
CN103254268A (zh) * 2013-05-16 2013-08-21 寿光市富康化学工业有限公司 一种制备度他雄胺的工艺
BR102013020508B1 (pt) 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
US11351155B2 (en) 2014-12-05 2022-06-07 Case Western Reserve University Compositions and methods of modulating s-nitrosylation
KR101590072B1 (ko) 2014-12-23 2016-01-29 한미약품 주식회사 두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
ES3037196T3 (en) * 2015-03-13 2025-09-30 Dow Global Technologies Llc Olefin oligomerisation process with a catalyst comprising a chromium complex with a phosphacycle-containing ligand
KR102503428B1 (ko) 2015-12-22 2023-02-24 한미약품 주식회사 두타스테라이드를 포함하는 경구용 연질 캡슐 제형용 포장재
WO2017160106A2 (fr) 2016-03-16 2017-09-21 한미약품 주식회사 Complexe en capsule dure contenant du dutastéride et de la tamsulosine et son procédé de préparation
KR101716878B1 (ko) 2016-05-12 2017-03-15 주식회사 유유제약 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
EP3548035A4 (fr) 2016-11-30 2020-07-22 Case Western Reserve University Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
US11633409B2 (en) 2017-09-01 2023-04-25 Jw Pharmaceutical Corporation Solid preparation comprising dutasteride and method for preparing same
KR101996597B1 (ko) 2017-10-13 2019-07-31 주식회사 유유제약 두타스테리드와 타다라필을 용해시킨 경구용 캡슐 제형의 복합제제
KR102281252B1 (ko) 2018-05-21 2021-07-23 (주)인벤티지랩 두타스테라이드를 포함하는 마이크로 입자 및 이의 제조 방법
WO2019225924A1 (fr) * 2018-05-21 2019-11-28 (주)인벤티지랩 Microparticules comprenant du dutastéride et procédé de préparation associé
EA202191422A1 (ru) 2018-11-21 2021-10-21 Кейс Вестерн Ризерв Юниверсити Композиции и способы модулирования активности короткоцепочечной дегидрогеназы
KR20200074759A (ko) 2018-12-17 2020-06-25 동국제약 주식회사 두타스테라이드를 함유하는 고형제제
PE20230777A1 (es) 2020-05-20 2023-05-09 Rodeo Therapeutics Corp Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta
WO2024144084A1 (fr) * 2022-12-26 2024-07-04 주식회사 유영제약 Composition pharmaceutique de dutastéride à dose élevée sous forme de comprimé pour administration hebdomadaire et son procédé de préparation

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4317817A (en) * 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
DK465481A (da) * 1980-11-21 1982-05-22 Hoffmann La Roche Fremgangsmaade til fremstilling af d-homostemoider
IL74365A (en) * 1984-02-27 1990-07-26 Merck & Co Inc 17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
ATE67503T1 (de) * 1984-02-27 1991-10-15 Merck & Co Inc 17-beta-substituierte-4-aza-5-alpha-androstenon und ihre anwendung als 5-alpha-reduktaseinhibitoren.
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
US4845104A (en) * 1986-11-20 1989-07-04 Merck & Co., Inc. Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
DE3780778T2 (de) * 1986-11-20 1993-01-14 Merck & Co Inc Topisches arzneimittel enthaltend 17-beta-methoxy-carbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one.
US5110939A (en) * 1987-01-28 1992-05-05 Smithkline Beecham Corporation Intermediates in the preparation of steriod 5-alpha-reductase inhibitors
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US4814324A (en) * 1987-03-06 1989-03-21 Merck & Co., Inc. Sterol inhibitors of testosterone 5α-reductase
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
EP0285382B1 (fr) * 1987-04-03 1994-04-13 Merck & Co. Inc. Traitement d'alopécia androgénique avec 17-bêta-n-monosubstitué-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones
US5041433A (en) * 1987-04-29 1991-08-20 Smithkline Beecham Corporation 11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
NZ225100A (en) * 1987-06-29 1991-09-25 Merck & Co Inc Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates
US4954446A (en) * 1988-05-25 1990-09-04 Smithkline Beecham Corporation Aromatic steroid 5-α-reductase inhibitors
WO1989011282A1 (fr) * 1988-05-25 1989-11-30 Smithkline Beckman Corporation INHIBITEURS DE 5-alpha-REDUCTASE STEROIDE AROMATIQUE
US5237061A (en) * 1988-10-31 1993-08-17 Merck & Co., Inc. Methods of synthesizing benign prostatic hypertropic agents and their intermediates
US4970205A (en) * 1988-12-23 1990-11-13 Smithkline Beecham Corporation Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US5026882A (en) * 1988-12-23 1991-06-25 Smithkline Beecham Corporation Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4966898A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US4966897A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
CA2023157A1 (fr) * 1989-08-21 1991-02-22 Gary H. Rasmusson 17 beta-acyl-4-aza-5-alpha-androst-1-ene-3-ones utilsiables comme inhibiteurs de l'alpha-reductase
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5021575A (en) * 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids
US5100917A (en) * 1989-12-29 1992-03-31 Merrell Dow Pharmaceuticals Inc. Novel a-nor-steroid-3-carboxylic acid derivatives
GB9002922D0 (en) * 1990-02-09 1990-04-04 Erba Carlo Spa 17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
EP0462662A3 (en) * 1990-06-20 1992-08-19 Merck & Co. Inc. 17beta-n-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
EP0462665A3 (en) * 1990-06-20 1993-06-30 Merck & Co. Inc. Selected 17beta-polyaroyl-4-aza-5alpha-androst-1-en-3-ones as steroidal reductase inhibitors
EP0462664A3 (en) * 1990-06-20 1992-11-25 Merck & Co. Inc. Specific 17beta-thiobenzoyl-4-aza-5alpha-androst-1-en-3-ones as antiandrogenic agents
NZ239141A (en) * 1990-08-01 1994-04-27 Merrell Dow Pharma 4-amino-delta-4,6-steroids; preparatory processes and pharmaceutical compositions
AU637247B2 (en) * 1990-08-01 1993-05-20 Merrell Dow Pharmaceuticals Inc. 4-amino-delta4-steroids and their use as 5alpha-reductase inhibitors
US5318961A (en) * 1990-08-01 1994-06-07 Merrell Dow Pharmaceuticals Inc. 4-amino-Δ4-steroids and their use as 5α-reductase inhibitors
US5091534A (en) * 1990-08-27 1992-02-25 Merck & Co., Inc. Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids
US5120847A (en) * 1990-08-27 1992-06-09 Merck & Co., Inc. Process for iodinating or brominating the α-methylenic carbon of a secondary amide
CA2050824A1 (fr) * 1990-09-24 1992-03-25 John M. Williams Methode de preparation de 3-oxo-4-azaandrost-1-en-17.beta.-ones
US5061801A (en) * 1990-09-24 1991-10-29 Merck & Co., Inc. Intermediate for making 3-oxo-4-aza-androst-1-ene 17β-ketones
US5061803A (en) * 1990-09-24 1991-10-29 Merck & Co., Inc. Process for making 17-beta alkanoyl 3-oxo-4-aza-5-α-androst-1-enes
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
WO1992018132A1 (fr) * 1991-04-17 1992-10-29 Merck & Co., Inc. Association pharmaceutique destinee au traitement de l'hyperplasie prostatique benigne et contenant un inhibiteur de 5 alpha-reductase
GB9115676D0 (en) * 1991-07-19 1991-09-04 Erba Carlo Spa Process for the preparation of 17 beta substituted-4-aza-5 alpha-androstan-3-one derivatives
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
ES2118222T3 (es) * 1991-12-20 1998-09-16 Glaxo Wellcome Inc Inhibidores de 5-alfa-testosterona reductasa.
JP3164389B2 (ja) * 1991-12-25 2001-05-08 三共株式会社 ４−アザステロイド類
JPH07508033A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド ５α−レダクターゼ阻害剤としての３−オキソ−４−アザステロイドの新規１７−エステル，アミド及びケトン誘導体
AU668181B2 (en) * 1992-05-20 1996-04-26 Merck & Co., Inc. Ester derivatives of 4-aza-steroids
EP0641204B1 (fr) * 1992-05-20 2000-08-16 Merck & Co. Inc. 17-ethers et thioethers de 4-aza-steroides
HUT71484A (en) * 1992-05-20 1995-11-28 Merck & Co Inc Process for producing of 7beta-substituted-4-aza-5alpha-cholestan-ones as 5-alpha-reductase inhibitors and pharmaceuticals compositions containing them
WO1993023420A1 (fr) * 1992-05-20 1993-11-25 Merck & Co., Inc. NOUVEAUX 4-AZA-5α-ANDROSTANE-3-ONES SUBSTITUES EN POSITION 7β EN TANT QU'INHIBITEURS DE LA 5α-REDUCTASE
JPH07508034A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド １７−アミノ置換４−アザステロイド５α−レダクターゼ阻害剤
AU672978B2 (en) * 1992-05-20 1996-10-24 Merck & Co., Inc. 4-azasteroid 5-alpha-reductase inhibitors
AU4251993A (en) * 1992-05-20 1993-12-13 Merck & Co., Inc. Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
JPH07508032A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド ５α−レダクターゼ阻害剤としての新規Δ−１７−及びΔ−２０オレフィン性並びに飽和１７β−置換４−アザ−５α−アンドロスタン−オン
HUT71514A (en) * 1992-05-21 1995-12-28 Endorecherche Inc Inhibitors of testosterone 5 alfa-reductase activity and pharmaceutical compositions containing the same
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9216329D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
AU5323694A (en) * 1992-10-06 1994-04-26 Merck & Co., Inc. 17beta -carboxanilides of 4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
IL107611A0 (en) * 1992-11-18 1994-02-27 Smithkline Beecham Corp Steroid compounds and pharmaceutical compositions containing them
AP459A (en) * 1992-12-18 1996-02-14 Glaxo Wellcome Inc Substituted 6-azaandrostenones.
US5380728A (en) * 1993-02-10 1995-01-10 Merck & Co., Inc. Aldehyde metabolite of 17β-N-monosubstituted-carbamoyl-4-aza-5α-a
US5438061A (en) * 1993-07-16 1995-08-01 Merck & Co., Inc. 7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones

Also Published As

Publication number Publication date
NL300122I1 (nl) 2003-06-02
CY2219B1 (en) 2003-04-18
PL313492A1 (en) 1996-07-08
DE69407978D1 (de) 1998-02-19
ZA947119B (en) 1995-05-26
NZ274642A (en) 1997-11-24
RU2140926C1 (ru) 1999-11-10
MY119778A (en) 2005-07-29
PL180002B1 (pl) 2000-11-30
WO1995007927A1 (fr) 1995-03-23
NO961080L (no) 1996-03-15
PE15095A1 (es) 1995-06-04
DE10399022I1 (de) 2004-01-15
SG52650A1 (en) 1998-09-28
EP0719278B1 (fr) 1998-01-14
CZ74596A3 (en) 1996-09-11
CY2004002I1 (el) 2009-11-04
JP2904310B2 (ja) 1999-06-14
HUT73850A (en) 1996-09-30
GR3026144T3 (en) 1998-05-29
TW369521B (en) 1999-09-11
DE69407978T2 (de) 1998-05-07
CN1057771C (zh) 2000-10-25
IL110978A0 (en) 1994-11-28
BG100410A (bg) 1996-09-30
NL300122I2 (nl) 2003-09-01
NO961080D0 (no) 1996-03-15
CY2004002I2 (el) 2009-11-04
FI961231L (fi) 1996-03-15
SK281869B6 (sk) 2001-08-06
NO2003003I2 (no) 2007-06-11
LU91027I2 (fr) 2004-04-28
DE10399022I2 (de) 2012-09-13
EP0719278A1 (fr) 1996-07-03
ES2113127T3 (es) 1998-04-16
KR100364953B1 (ko) 2003-04-08
ZA947118B (en) 1995-05-26
RO117455B1 (ro) 2002-03-29
DK0719278T3 (da) 1998-09-14
BR1100329A (pt) 2000-06-13
HRP940563A2 (en) 1997-02-28
CA2170047A1 (fr) 1995-03-23
CA2462061A1 (fr) 1995-03-23
HU220060B (hu) 2001-10-28
HU9600656D0 (en) 1996-05-28
US5565467A (en) 1996-10-15
IL110978A (en) 1999-01-26
JPH09502731A (ja) 1997-03-18
IS1713B (is) 1998-12-30
CZ286069B6 (cs) 2000-01-12
SA94150231B1 (ar) 2005-05-04
AU690925B2 (en) 1998-05-07
BG62363B1 (bg) 1999-09-30
CA2170047C (fr) 2004-11-09
HK1004334A1 (en) 1998-11-20
AP9400669A0 (en) 1994-10-31
CN1131424A (zh) 1996-09-18
AP494A (en) 1996-05-15
SI0719278T1 (sl) 1998-06-30
OA10575A (en) 2002-06-25
US5846976A (en) 1998-12-08
ATE162199T1 (de) 1998-01-15
FI961231A0 (fi) 1996-03-15
EE03241B1 (et) 1999-12-15
IS4205A (is) 1995-03-18
AU7875194A (en) 1995-04-03
FI115216B (fi) 2005-03-31
NO306117B1 (no) 1999-09-20
SK34796A3 (en) 1996-07-03

Similar Documents

Publication Publication Date Title
HRP940563B1 (en) Androstenone derivatives
IL122339A0 (en) Thiohydantoine derivatives
AP9400622A0 (en) Substituted azolone derivatives
HU9400724D0 (en) 2-thio-substituted carbapeneme derivatives
GB9305306D0 (en) Pyrrolo-pyridazione derivatives
ZA945504B (en) Benzocarbocyclic derivatives
HU9300744D0 (en) 2-oxo-quinoline derivatives
HU9301112D0 (en) Propenoyl-imidazole derivatives
ZA945589B (en) 2-phenylpyrrole derivatives
ZA947183B (en) 3-aryl-4-hydroxy-Delta3-dihydrofuranone derivatives
GB2271564B (en) Thioalkylthio carbacephalosporin derivatives
GB2270913B (en) Chlordifluoromethoxyphenyl derivatives
ZA947128B (en) Hydroxyethyl-azolyl derivatives
HU9402534D0 (en) New naphtoxazine derivatives
ZA945588B (en) 2-Phenylpyrrole derivatives
EP0565961A3 (en) Ethyl-triazolyl derivatives
GB2274282B (en) Piperazine-and piperidine-isoxazole derivatives
GB9304440D0 (en) 2-acyloxycephem derivatives
GB9223244D0 (en) Phenylpyrazine derivatives
HU9301696D0 (en) Pyrimidofuroxane derivatives
IL110645A0 (en) Azoxycyanobenzodioxane derivatives
GB9311613D0 (en) Thienylthiazole derivatives
IL108525A0 (en) Lyxofuranosyl derivatives
HU9401940D0 (en) Rifamycin-36 derivatives
GB9322238D0 (en) Enthanolamine derivatives

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: GLAXO WELLCOME INC., US

B1PR Patent granted
PPPP Transfer of rights

Owner name: SMITHKLINE BEECHAM CORPORATION, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20130909

Year of fee payment: 20

PNAN Change of the applicant name, address/residence

Owner name: GLAXOSMITHKLINE LLC, US

PPPP Transfer of rights

Owner name: GLAXO GROUP LIMITED, GB

PB20 Patent expired after termination of 20 years

Effective date: 20140916